IRA Drug Pricing Implications Impact Pharma Views On Deal Terms, Valuations
VCs Consider Risk, Have Not Shifted Investment Strategies
Executive Summary
Pharma business development executives and venture capital investors shared their thoughts on the Inflation Reduction Act at Biocom’s Global Life Science Partnering and Investor Conference in San Diego.
You may also be interested in...
Finance Watch: Q4 Venture Financings Slumped But 2024 Outlook Is Optimistic
Private Company Financings: Year-end data from Pitchbook/NVCA, like recent Evaluate numbers, show venture fundraising slid from the third to fourth quarters. However, Taiho increased its VC fund by $100m, Ji Xing closed a $162m series D round and MAPS raised more than $100m.
As Time Ticks, Industry Edges Closer To The Big Patent Cliff
Big pharma manufacturers are approaching a period that will be marked by the loss of exclusivity of many big-selling brands. All of the players are looking for ways to navigate the loss of revenues.
Bayer Sharpens US Focus As Pressure Tightens On Drug Makers
The German company’s two top sellers are marketed by partners in the US, but Bayer will pocket all US sales from its four newest products, at a time when pressures are mounting at home and abroad.